Last updated: September 8, 2026
Benzoyl peroxide 5% and erythromycin 3% is an established topical acne combination historically marketed as Benzamycin. Its commercial profile is mature, genericized, and price competitive. The active-ingredient combination has limited remaining patent value, no meaningful biologic or biosimilar exposure, and low probability of attracting large-scale branded investment. Revenue is concentrated in generic topical products, pharmacy dispensing, dermatology prescriptions, and contract-manufactured formulations.
The main commercial risks are generic price erosion, substitution by newer topical combinations, declining reliance on topical antibiotics because of antimicrobial-resistance concerns, and payer preference for lower-cost generic products. Growth opportunities are concentrated in reformulation, improved packaging, private-label supply, and international markets rather than in exclusivity-driven pricing.
What is benzoyl peroxide and erythromycin used for?
Benzoyl peroxide and erythromycin is a topical prescription treatment for acne vulgaris. The conventional formulation contains benzoyl peroxide 5% and erythromycin 3%, generally supplied as a gel or as a two-component system that is mixed before dispensing.
Benzoyl peroxide has antimicrobial and comedolytic activity. Erythromycin is a macrolide antibiotic that suppresses Cutibacterium acnes and inflammatory acne lesions. Benzoyl peroxide is also used to reduce the risk of antibiotic resistance associated with topical antibiotic therapy.
The combination is generally used for inflammatory acne, particularly when topical retinoids alone are insufficient or poorly tolerated. Current acne treatment guidelines place greater emphasis on limiting topical antibiotic duration and combining antibiotic therapy with benzoyl peroxide.[1]
What products contain benzoyl peroxide and erythromycin?
| Product or product type |
Active ingredients |
Typical strength |
Commercial status |
| Benzamycin topical gel |
Erythromycin plus benzoyl peroxide |
3% / 5% |
Legacy branded product; generic competition |
| Generic erythromycin and benzoyl peroxide gel |
Erythromycin plus benzoyl peroxide |
3% / 5% |
Prescription generic |
| Benzoyl peroxide-only products |
Benzoyl peroxide |
Commonly 2.5%, 5%, or 10% |
Broad OTC and prescription competition |
| Erythromycin-only topical products |
Erythromycin |
Commonly 2% |
Generic prescription competition |
| Alternative acne combinations |
Clindamycin, adapalene, tretinoin, benzoyl peroxide |
Varies |
Stronger competitive set |
What is the FDA regulatory status of benzoyl peroxide and erythromycin?
The combination is an FDA-regulated prescription topical drug rather than a simple OTC benzoyl peroxide product. Benzoyl peroxide alone is widely available under the FDA OTC acne monograph, but the addition of erythromycin places the combination in a prescription-drug framework.[2]
The product is not a biologic. It does not create biosimilar substitution risk, and its regulatory pathway is based on conventional drug approval and generic abbreviated new drug applications.
FDA regulatory dynamics are shaped by:
- Generic approval under the ANDA pathway.
- Demonstration of pharmaceutical equivalence and bioequivalence or equivalent performance.
- Stability requirements for erythromycin and benzoyl peroxide.
- Packaging requirements because benzoyl peroxide can oxidize or degrade formulation components.
- Potential product-specific guidance for topical semisolid drug products.
FDA’s Orange Book should be reviewed for current reference-listed-drug status, therapeutic-equivalence codes, and any listed patents or exclusivity. For mature topical products, the commercial value of Orange Book listings is usually limited because core composition patents have expired and remaining protection is more likely to concern formulation or manufacturing details.[3]
What patents protect benzoyl peroxide and erythromycin?
The foundational composition technology is old and is not expected to provide meaningful current exclusivity in the United States. The original Benzamycin-era patents and related formulation rights generally fall within an expired or commercially exhausted patent period.
| Patent category |
Current commercial relevance |
| Core erythromycin-benzoyl peroxide composition |
Low; foundational protection is expected to have expired |
| Basic topical gel formulation |
Low to moderate; older rights are generally expired |
| Mixing and packaging systems |
Potentially relevant for specific products, but narrow |
| Stability-enhancing excipients |
Potentially relevant where separately patented |
| Manufacturing process |
Usually a secondary barrier and often difficult to enforce commercially |
| Method-of-use patents for acne |
Low; broad acne-use rights are generally old |
| Device or dispensing system |
May create limited product differentiation |
| Pediatric or regulatory exclusivity |
No major current exclusivity expected for the legacy combination |
A complete live patent opinion cannot be based on the active ingredients alone. It requires a current review of the specific reference-listed drug, FDA Orange Book entries, USPTO assignment records, and relevant national patent registers. The commercially important conclusion is that the active-ingredient combination is not a high-value, exclusivity-protected asset.
Are there formulation patents for the combination?
Formulation patents can cover:
- Premixed versus separately packaged gels.
- Water activity and preservative systems.
- Erythromycin stabilization.
- Benzoyl peroxide particle size.
- Vehicle composition.
- Packaging that limits oxygen, light, or moisture exposure.
- Reconstitution or mixing mechanisms.
- Improved storage stability.
These rights may delay direct replication of a particular branded presentation. They do not generally restore broad market exclusivity for the active ingredients. A generic manufacturer can often design around narrow formulation claims by changing excipients, packaging, viscosity, or manufacturing conditions.
Are there method-of-use patents for acne treatment?
Broad method-of-use protection for treating acne with benzoyl peroxide and erythromycin is unlikely to remain commercially material. Any surviving method claims would need to be narrow, such as a defined dosing schedule, patient population, treatment duration, or resistance-management protocol. Such claims would also face enforcement challenges because topical acne prescribing is highly substitutable.
When does benzoyl peroxide and erythromycin lose exclusivity?
The product has already passed the period in which conventional small-molecule exclusivity would drive premium pricing. Its commercial exclusivity was lost through the expiration of foundational patents, regulatory exclusivity, and the entry of generic topical products.
The practical exclusivity timeline is:
| Period |
Market event |
Financial effect |
| Initial launch period |
Branded prescription combination introduced |
Premium pricing and physician familiarity |
| Patent and regulatory protection period |
Limited competition |
Higher gross margins |
| Generic entry period |
ANDA approvals and pharmacy substitution |
Rapid price compression |
| Mature generic period |
Multiple suppliers and private-label distribution |
Low unit economics |
| Current market |
Formulation, supply, and brand-recognition competition |
Limited pricing power |
There is no meaningful new chemical entity exclusivity for this combination today. Any commercial protection depends on product-specific formulation, packaging, supply agreements, or brand positioning.
How many patents cover benzoyl peroxide and erythromycin?
No reliable commercial count can be assigned without limiting the analysis by jurisdiction, product, assignee, claim status, and patent family. A keyword search would overstate protection by including expired patents, abandoned applications, foreign counterparts, and unrelated benzoyl peroxide or erythromycin inventions.
For United States market analysis, the relevant count should include only:
- Unexpired U.S. patents.
- Patents listed against the relevant FDA reference product.
- Claims covering the marketed strength and dosage form.
- Active continuation or divisional patents.
- Enforceable formulation, packaging, or manufacturing claims.
The expected result for the legacy 3% erythromycin and 5% benzoyl peroxide combination is a low-value estate rather than a dense, blocking patent portfolio.
Which companies are challenging the product?
Competition comes primarily from generic manufacturers and alternative acne brands rather than from named litigation challengers.
Generic competition
Potential suppliers include companies active in topical dermatology and generic semisolids, such as:
- Perrigo
- Taro Pharmaceutical Industries
- Prasco Laboratories
- Tolmar
- Teva Pharmaceuticals
- Viatris
- Mylan legacy operations
- Contract manufacturers and private-label suppliers
The exact supplier list depends on the current FDA product database, distributor inventory, pharmacy contracts, and national market. Product availability can change quickly because topical semisolid manufacturing is concentrated among a limited number of approved facilities.
Therapeutic competition
The combination competes with:
- Benzoyl peroxide monotherapy.
- Clindamycin and benzoyl peroxide combinations.
- Adapalene and benzoyl peroxide.
- Tretinoin and benzoyl peroxide regimens.
- Clindamycin, adapalene, or tretinoin monotherapy.
- Oral doxycycline and other systemic acne treatments.
- Newer topical agents such as azelaic acid, clascoterone, and sarecycline in selected patients.
The most important direct competitive threat is clindamycin/benzoyl peroxide. It has stronger contemporary prescribing familiarity in many dermatology practices, although it carries the same stewardship concern associated with topical antibiotic exposure.
What is the Orange Book status of benzoyl peroxide and erythromycin?
The Orange Book status depends on the specific reference-listed drug and current FDA listing. The combination is generally treated as an older prescription topical product with generic competition rather than as a product protected by active, high-value listed patents.
Relevant Orange Book questions include:
- Whether a current reference-listed drug remains active.
- Which products have therapeutic-equivalence designations.
- Whether any patent is listed for the reference product.
- Whether a 30-month stay has been triggered by a Paragraph IV certification.
- Whether a generic is designated therapeutically equivalent or merely pharmaceutically equivalent.
For a mature topical combination, Paragraph IV litigation is less likely to be commercially significant than in high-revenue oral drugs. A generic applicant may use Paragraph IV certification if it challenges a listed patent, but the market size usually limits the economic incentive for prolonged litigation.
What patent litigation affects benzoyl peroxide and erythromycin?
No major, current U.S. patent dispute is broadly associated with the legacy erythromycin-benzoyl peroxide combination at the level of commercially important oral-drug litigation. Any litigation is more likely to involve:
- Formulation equivalence.
- ANDA approval timing.
- Labeling or method-of-use language.
- Trade dress and trademark rights.
- Product availability or manufacturing disputes.
- Patent claims directed to stability or packaging.
The absence of a prominent current litigation campaign is consistent with a mature generic market and limited remaining exclusivity value.
Are there settlement agreements involving generic entry?
No widely recognized settlement agreement currently defines the U.S. market for the legacy combination. If a product-specific Paragraph IV settlement exists, its commercial effect would depend on the exact reference product, generic applicant, patent claims, and agreed launch date. Such agreements are not normally decisive for a low-revenue topical combination unless the branded product has a protected formulation or controlled distribution channel.
What is the financial trajectory of benzoyl peroxide and erythromycin?
Public product-level revenue data are generally unavailable because the combination is sold by multiple generic suppliers and is not reported as a standalone segment by major pharmaceutical companies.
The financial trajectory can be assessed using market structure:
| Financial driver |
Direction |
Effect |
| Brand-to-generic conversion |
Negative |
Reduces average selling price |
| Multiple generic suppliers |
Negative |
Increases pharmacy and payer bargaining power |
| Dermatology prescription volume |
Stable to declining |
Limits unit growth |
| OTC benzoyl peroxide substitution |
Negative |
Shifts treatment away from the combination |
| Packaging and formulation differentiation |
Positive but narrow |
Supports modest price premiums |
| Private-label manufacturing |
Positive for efficient suppliers |
Increases volume but compresses margins |
| Antibiotic-stewardship pressure |
Negative |
Limits long-term use |
| International access markets |
Mixed |
Volume opportunity with lower prices |
The product can generate dependable but modest cash flow for a low-cost manufacturer with an efficient topical facility. It is less attractive for a branded pharmaceutical company seeking premium growth. Gross margins depend on plant utilization, raw-material costs, packaging, stability controls, regulatory maintenance, and the number of active competitors.
What is the revenue exposure for manufacturers?
Revenue exposure is typically limited because:
- No single supplier controls the active ingredients.
- The product is substitutable with other acne therapies.
- Payers can move prescriptions to alternative generic products.
- Retail pricing varies by pharmacy and insurance channel.
- Product-level reporting is usually aggregated into generic dermatology revenue.
A manufacturer with an approved formulation can still benefit from recurring prescriptions, but the asset is unlikely to materially affect the valuation of a diversified pharmaceutical company unless it is part of a larger dermatology portfolio.
How does this product compare with competing acne drugs?
| Product |
Main advantage |
Main weakness |
Patent and pricing profile |
| Erythromycin plus benzoyl peroxide |
Established combination; resistance mitigation from benzoyl peroxide |
Older antibiotic; limited differentiation |
Mature generic |
| Clindamycin plus benzoyl peroxide |
Familiar prescribing and strong acne efficacy |
Antibiotic stewardship concerns |
Generic, with some branded formulations |
| Adapalene plus benzoyl peroxide |
Retinoid and antimicrobial combination |
Irritation and tolerability issues |
Generic and branded competition |
| Benzoyl peroxide alone |
Low cost and OTC access |
Less effective for some inflammatory disease |
Highly commoditized |
| Tretinoin products |
Strong comedolytic efficacy |
Irritation and adherence challenges |
Mostly generic |
| Clascoterone |
Non-antibiotic hormonal mechanism |
Higher cost and newer market position |
Branded, stronger remaining exclusivity |
| Oral doxycycline |
Effective for moderate inflammatory acne |
Systemic adverse effects and stewardship limits |
Generic |
The combination’s strongest commercial position is as a low-cost topical option. Its weakest position is against newer, non-antibiotic therapies with better differentiation and against inexpensive benzoyl peroxide monotherapy.
What generic launch risks exist?
A new generic entrant would face moderate regulatory and manufacturing risk but low patent risk.
Key barriers include:
- Demonstrating equivalent performance for a complex topical semisolid.
- Matching viscosity, particle distribution, phase behavior, and drug release.
- Maintaining erythromycin stability during shelf life.
- Preventing benzoyl peroxide degradation.
- Establishing container-closure compatibility.
- Securing reliable topical manufacturing capacity.
- Obtaining pharmacy and wholesaler placement.
- Avoiding rapid price erosion after launch.
The main launch scenario is a low-price entry followed by additional supplier entry and declining net prices. A differentiated package, longer shelf life, improved storage conditions, or a more convenient mixing system could improve margins.
What licensing deals affect the product?
No major recent licensing transaction is generally associated with the legacy benzoyl peroxide and erythromycin combination. Licensing value would most likely arise from:
- A proprietary vehicle.
- A stability-enhancing delivery system.
- A controlled-release topical platform.
- A dermatology portfolio acquisition.
- Regional commercialization rights.
- Contract manufacturing and private-label agreements.
A standalone license for the old active-ingredient combination would have limited strategic value unless paired with manufacturing capacity, a strong dermatology sales force, or a differentiated formulation.
What manufacturing and geographic barriers affect the market?
The market is geographically fragmented. U.S. generic approval does not create automatic access in Europe, Canada, Japan, or emerging markets. Each jurisdiction may apply different standards for topical equivalence, labeling, antibiotic use, and prescription status.
Manufacturing barriers include:
- Specialized semisolid mixing and homogenization.
- Controlled peroxide handling.
- Stability testing.
- Packaging compatible with oxidizing ingredients.
- Microbiological control.
- Batch-to-batch viscosity consistency.
- Regulatory inspection readiness.
Geographic growth is more likely in markets where acne treatment access is expanding and generic topical manufacturing is underdeveloped. Price levels are lower, but local partnerships can reduce registration and distribution costs.
Key Takeaways
- Benzoyl peroxide 5% and erythromycin 3% is a mature prescription acne combination historically associated with Benzamycin.
- Foundational composition and use patents are not expected to provide meaningful current U.S. exclusivity.
- The product has no biosimilar risk because it is a conventional small-molecule topical drug.
- Generic competition, alternative acne therapies, and antibiotic stewardship limit revenue growth.
- Product-level revenue is generally not publicly reported.
- The commercial opportunity is strongest for efficient generic manufacturers, private-label suppliers, and differentiated formulations.
- The main technical barriers are stability, semisolid equivalence, packaging, and manufacturing consistency.
- A new entrant would face more price and execution risk than patent risk.
FAQs About Benzoyl Peroxide and Erythromycin
Is benzoyl peroxide and erythromycin still prescribed?
Yes. It remains an available topical acne treatment, although clinicians increasingly limit topical antibiotic duration and pair antibiotic therapy with benzoyl peroxide to reduce resistance risk.
Is benzoyl peroxide and erythromycin available over the counter?
The combination is generally prescription-only. Benzoyl peroxide-only acne products are widely available over the counter.
Can a generic manufacturer obtain FDA approval for the combination?
Yes. A manufacturer can pursue an ANDA for a reference-listed topical product, subject to FDA requirements for pharmaceutical equivalence, bioequivalence or equivalent performance, stability, labeling, and manufacturing quality.
Does benzoyl peroxide and erythromycin have biosimilar competition?
No. Biosimilar rules apply to biologic products. This combination is a conventional small-molecule topical drug and competes through generic drug pathways.
What is the largest commercial threat to the combination?
The largest threat is substitution by lower-cost benzoyl peroxide products, other generic topical combinations, and newer non-antibiotic acne therapies rather than patent litigation.
References
- American Academy of Dermatology Association. (2024). Acne clinical guideline. https://www.aad.org/member/clinical-quality/guidelines/acne
- U.S. Food and Drug Administration. (2024). Over-the-counter acne drug products: Monograph conditions. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-333
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- National Library of Medicine. (2024). DailyMed: Current medication labeling. https://dailymed.nlm.nih.gov/dailymed/
- Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., Keri, J. E., Leyden, J. J., Reynolds, R. V., Silverberg, N. B., Stein Gold, L. F., Tollefson, M. M., Weiss, J. S., Dolan, N. C., Sagan, A. A., Stern, M., & Bhushan, R. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.e33. https://doi.org/10.1016/j.jaad.2015.12.037
